Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies with leads to lower progression‐free survival† compared with without anti‐PD1 monoclonal antibodies (high certainty).
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
BRAF plus MEK inhibitors probably leads to lower progression‐free survival† compared with BRAF inhibitors (moderate certainty).
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
Anti‐PD1 monoclonal antibodies leads to lower progression‐free survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).